BIIB vs NBIX
Figures are each company’s own, from its most recent annual filing; fiscal year ends differ. Both are classified by the SEC under Biological Products, (No Diagnostic Substances).
| Metric | BIIBBIOGEN INC. | NBIXNEUROCRINE BIOSCIENCES INC |
|---|---|---|
| Revenue | $9.89B | $2.86B |
| Gross margin | 75.7% | 98.2% |
| Operating income | Unavailable | $619.10M |
| Operating margin | Unavailable | 21.6% |
| Net income | $1.29B | $478.60M |
| Net margin | 13.1% | 16.7% |
| Free cash flow | $2.05B | $748.70M |
| Total assets | $29.44B | $4.63B |
| Total equity | $18.26B | $3.25B |
| Diluted EPS | $8.79 | $4.67 |
Every figure links to the filing it came from on each company page: BIIB and NBIX. See the methodology for how each one is chosen.